Evaluation of Immunosuppression in Septic Shock: Biomarkers and Pharmacological Restoration (IMMUNOSEPSIS)

• Conditions: Immunology of Septic Shock
• Interventions: Other: Circulating blood (leukocytes)

• Registration Number: NCT02803346
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

Septic syndromes (systemic inflammatory response associated with infection) remain a major although largely under-recognized health care problem and represent the first cause of mortality in intensive care units. While it has long been known that sepsis deeply perturbs immune homeostasis by inducing a tremendous systemic inflammatory response, novel findings indicate that sepsis indeed initiates a more complex immunologic response that varies over time, with the concomitant occurrence of both pro- and anti-inflammatory mechanisms. As a resultant, after a short pro-inflammatory phase, septic patients enter a stage of protracted immunosuppression. This is illustrated in those patients by reactivation of dormant viruses (CMV or HSV) or infections due to pathogens, including fungi, which are normally pathogenic solely in immunocompromised hosts. These alterations might be directly responsible for worsening outcome in patients who survived initial resuscitation as nearly all immune functions are deeply compromised. Both arms of immunity (innate and adaptive) are indeed markedly suppressed (including enhanced leukocyte apoptosis, lymphocyte anergy and deactivated monocyte functions). New promising therapeutic avenues are currently emerging from those recent findings such as adjunctive immunostimulation for the most immunosuppressed patients. The prerequisite for immunostimulation administration (IFNg, GM-CSF, IL-7) however relies on the investigators capacity in identifying the patients who could benefit from it, as there is no clinical sign of immune dysfunctions. The main objectives are:

1. to identify the best biomarkers for sepsis-induced immunosuppression and

2. to evaluate ex vivo whether drugs could rejuvenate immune functions.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2009-01
• Status Verified: 2016-06
• Study First Submitted: 2016-06-14
• Study First Submitted QC: 2016-06-15
• Last Update Submitted: 2016-06-15
• Study First Posted: 2016-06-16
• Last Update Posted: 2016-06-16
• Primary Completion: 2016-12
• Study Completion: 2016-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 160

Inclusion Criteria

• septic shock is defined by an identifiable site of infection, persisting hypotension despite fluid resuscitation requiring vasopressor therapy, and evidence of a systemic inflammatory response

Read More

Exclusion Criteria

• age < 18
• immunosuppressive disease (HIV, cancer, primary immune deficiency)
• immunosuppressive treatment or corticoid treatment (dosage > 10mg/day or cumulative dose >700 mg equivalent prednisolone)
• aplasia as defined by number of circulating neutrophils < 500 cells / mm3
• extracorporeal circulation during the month prior ICU admission

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
septic shock patients	Circulating blood (leukocytes)	-

Primary Outcome Measures

Name	Time	Method
mortality	28 days post diagnosis

Secondary Outcome Measures

Name	Time	Method
occurrence of nosocomial infection	28 days post diagnosis
decreased monocyte HLA-DR expression	day 3 post diagnosis

Trial Locations

Locations (1)

Hospices Civils de Lyon - Hopital Edouard Herriot; 🇫🇷 Lyon, France